Product Description
Bemcentinib has been studied in 179 hospitalized patients with COVID-19 compared with standard-of-care therapies.Ê Preliminary data indicate that bemcentinib in addition to standard of care therapies provides added sustained protection against worsening of lung damage in patients who need of oxygen treatment, thus reducing the chances of needing a ventilator to help their breathing and aiding in their recovery. (Sourced from: https://www.bergenbio.com/pipeline/bemcentinib-covid-19/)
Mechanisms of Action: AXL Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: Fast Track - Lung Cancer|Non-Small-Cell Lung Cancer|Oncology Solid Tumor Unspecified|Small Cell Lung CancerFast Track - Non-Small-Cell Lung Cancer|Small Cell Lung Cancer *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: BerGenBio AS
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: France, Greece, Hungary, Italy, Norway, Poland, Spain, United States
Active Clinical Trial Count: 4
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Melanoma|Non-Small-Cell Lung Cancer
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT02922777 |
STU 052015-077 | P1 |
Completed |
Non-Small-Cell Lung Cancer |
2023-02-06 |
2% |
2024-02-22 |
Primary Endpoints|Study Completion Date|Treatments|Trial Status |
NCT02872259 |
NCT02872259 | P2 |
Completed |
Melanoma |
2024-05-23 |
48% |
2024-06-28 |
Primary Completion Date|Primary Endpoints |
2024-511007-41-00 |
BGBC016 | P2 |
Completed |
Non-Small-Cell Lung Cancer |
2025-02-25 |
2025-05-02 |
Treatments |
|
2015-002615-15 |
Combination study of BGB324 in melanoma | P2 |
Completed |
Melanoma |
2024-05-23 |